m6A-modification of cyclin D1 and c-myc IRESs in glioblastoma controls ITAF activity and resistance to mTOR inhibition
Related Posts
Hortobagyi GN, Lacko A, Sohn J, Cruz F, Borrego MR, Manikhas A, Park YH, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia[...]
Finn RS, Qin S, Piscaglia F, Evans TRJ, Knox JJ, López López C, Ramji Z, Ren M, Mody K, Vogel A, Kudo M. Characterization of[...]
Finn RS, Kudo M, Barnes G, Meyer T, Boisserie F, Abdrashitov R, Chen Y, Li S, Zhu AX, Qin S, Vogel A. Tislelizumab versus Sorafenib[...]